41,400 Shares in Adaptive Biotechnologies Corporation $ADPT Bought by Leeward Financial Partners LLC

Leeward Financial Partners LLC acquired a new position in shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) in the 2nd quarter, HoldingsChannel reports. The institutional investor acquired 41,400 shares of the company’s stock, valued at approximately $888,000.

Other large investors have also bought and sold shares of the company. 1492 Capital Management LLC bought a new position in shares of Adaptive Biotechnologies in the fourth quarter worth about $1,484,000. Jupiter Asset Management Ltd. grew its holdings in shares of Adaptive Biotechnologies by 33.8% during the 4th quarter. Jupiter Asset Management Ltd. now owns 362,811 shares of the company’s stock valued at $5,892,000 after purchasing an additional 91,683 shares during the last quarter. Rhenman & Partners Asset Management AB increased its position in Adaptive Biotechnologies by 22.2% during the 4th quarter. Rhenman & Partners Asset Management AB now owns 605,000 shares of the company’s stock worth $9,825,000 after purchasing an additional 110,000 shares in the last quarter. Westfield Capital Management Co. LP acquired a new position in Adaptive Biotechnologies during the 4th quarter worth approximately $65,942,000. Finally, Jennison Associates LLC lifted its stake in Adaptive Biotechnologies by 103.9% in the 4th quarter. Jennison Associates LLC now owns 2,674,668 shares of the company’s stock valued at $43,437,000 after purchasing an additional 1,363,181 shares during the last quarter. 99.17% of the stock is owned by institutional investors and hedge funds.

Adaptive Biotechnologies Trading Up 1.1%

Shares of NASDAQ ADPT opened at $24.74 on Friday. The company has a debt-to-equity ratio of 2.22, a quick ratio of 4.68 and a current ratio of 4.79. Adaptive Biotechnologies Corporation has a 52-week low of $11.92 and a 52-week high of $26.16. The firm has a 50 day moving average price of $21.28 and a two-hundred day moving average price of $17.12. The stock has a market cap of $3.95 billion, a P/E ratio of -60.34 and a beta of 2.08.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its quarterly earnings results on Wednesday, July 29th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.12). The business had revenue of $71.55 million for the quarter, compared to the consensus estimate of $65.44 million. Adaptive Biotechnologies had a negative net margin of 20.73% and a negative return on equity of 36.81%. Adaptive Biotechnologies’s revenue was up 21.5% on a year-over-year basis. During the same period in the previous year, the business posted ($0.17) EPS. As a group, equities analysts forecast that Adaptive Biotechnologies Corporation will post -0.4 EPS for the current year.

Analyst Upgrades and Downgrades

ADPT has been the topic of a number of research analyst reports. Piper Sandler raised their target price on shares of Adaptive Biotechnologies from $20.00 to $27.50 and gave the company an “overweight” rating in a research report on Tuesday, August 4th. Morgan Stanley increased their price target on Adaptive Biotechnologies from $20.00 to $22.00 and gave the company an “equal weight” rating in a research note on Thursday, July 30th. BTIG Research raised their price objective on Adaptive Biotechnologies from $24.00 to $25.00 and gave the company a “buy” rating in a report on Thursday, July 30th. Guggenheim raised their price objective on Adaptive Biotechnologies from $22.00 to $25.00 and gave the company a “buy” rating in a report on Thursday, July 30th. Finally, JPMorgan Chase & Co. lowered their target price on Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating for the company in a report on Wednesday, May 6th. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $24.42.

Insider Buying and Selling

In other Adaptive Biotechnologies news, insider Susan Bobulsky sold 3,000 shares of the company’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $25.00, for a total value of $75,000.00. Following the sale, the insider owned 396,989 shares in the company, valued at approximately $9,924,725. The trade was a 0.75% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Sharon Benzeno sold 154,768 shares of the company’s stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $21.14, for a total value of $3,271,795.52. Following the completion of the sale, the insider owned 221,278 shares in the company, valued at $4,677,816.92. This trade represents a 41.16% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 1,310,086 shares of company stock valued at $27,934,739. Company insiders own 5.70% of the company’s stock.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.